Background Patients with cirrhosis are at high readmission risk. Using a large statewide database, we evaluated the effect of hospital cirrhosis-related patient volume on 30-day readmissions in patients with cirrhosis. Methods We conducted a retrospective study of the Healthcare Cost and Utilization Project State Inpatient Database for adult patients with cirrhosis, as defined by International Classification of Diseases, Ninth Revision (ICD-9) codes, hospitalized in California between 2009 and 2011. Multivariable logistic regression analysis was performed to evaluate the effect of hospital volume on 30-day readmissions. Results A total of 69,612 patients with cirrhosis were identified in 405 hospitals; 24,062 patients were discharged from the top 10% of hospitals (N = 41) by cirrhosis volume, and 45,550 patients in the bottom 90% (N = 364). Compared with highervolume centers, lower-volume hospitals cared for patients with similar average Quan-Charlson-Deyo (QCD) comorbidity scores (6.54 vs. 6.68), similar proportion of hepatitis B and fatty liver disease, lower proportion of hepatitis C (34.8 vs. 41.5%) but greater proportion of alcoholic liver disease (53.1 vs. 47.4%). Multivariable logistic regression analysis demonstrated admission to a lower-volume hospital did not predict 30-day readmission (odds ratio [OR] 0.97, 95% confidence interval [CI] 0.92-1.01) after adjusting for sociodemographics, QCD score, cirrhosis severity, and hospital characteristics. Instead, liver transplant center status significantly decreased the risk of readmission (OR 0.87, 95% CI 0.80-0.94). Ascites, hepatic encephalopathy, hepatocellular carcinoma, higher QCD, and presence of alcoholic liver disease and hepatitis C were also independent predictors. Conclusions Readmissions within 30 days were common among patients with cirrhosis hospitalized in California. While hospital cirrhosis volume did not predict 30-day readmissions, liver transplant center status was protective of readmissions. Medically complicated patients with cirrhosis at hospitals without liver transplant centers may benefit from additional support to prevent readmission.
Introduction
The economic burden of chronic liver disease and decompensated cirrhosis is significant, accounting for upwards of $2.5 billion a year in health care-related spending in the USA alone [1] [2] [3] [4] . As part of an ongoing effort to improve health care quality and consistency, it is essential to identify and understand gaps in the care of patients with cirrhosis. Readmission rates have been identified as a potential area of improvement [2] . Patients with decompensated cirrhosis patients experience hospital readmissions at higher-thanaverage rates, estimated in one study to be 14% at 7 days and up to 37% at 30 days [5] [6] [7] [8] [9] .
Reducing readmission rates not only improves quality of life and the burden of disease but has become essential in controlling health care-related expenditures in the context of value-based compensation [10, 11] . Several initiatives have been explored to reduce the rate of readmission, such as early outpatient follow-up and the use of paper or electronic checklists for cirrhotic complications including upper gastrointestinal bleeding or hepatic encephalopathy [1, 12, 13] .
Several hospital factors have been found to affect clinical outcomes for several medical conditions. Greater hospital volumes are associated with improved mortality for surgical procedures including heart valve replacement and nephrectomy as well as medical conditions such as congestive heart failure, pneumonia, and acute myocardial infarction [14, 15] . In congestive heart failure, increased hospital experience and expertise with cardiac management have been associated with reduced 30-day readmission rates [16] . Based on observations from this literature, our study leverages a large statewide database to evaluate the effect of hospital size and experience on readmission rates for patients with cirrhosis.
Methods
This study was conducted using data obtained through the Healthcare Cost and Utilization Project (HCUP), a database compiled and maintained by the Agency for Healthcare Index hospitalizations for adults (age ≥ 18 years) admitted with a diagnosis of cirrhosis were identified using the International Classification of Diseases, 9th RevisionClinical Modification (ICD-9-CM), and validated protocols by Tapper et al. [5] and Mellinger et al. [13] . The specific ICD-9 codes used for cirrhosis were 571.2, 571.5, and 571.6. Exclusion criteria included mortality during the index hospitalization, an admission within 30 days prior to the index admission, records containing corrupted data, and history of liver transplant (ICD9-CM V42.7, 50.5, 50.51, 50.59) (Fig. 1) .
The primary outcome measured was the 30-day readmission rate. To study the effect of hospital volume as a marker of experience for cirrhosis management, we defined hospital volume as the number of unique patients admitted for cirrhosis-related hospitalizations to each hospital. Cirrhosis-related hospitalizations were defined as any 
Statistical Analysis
For all analyses, a p value of < 0.05 was considered significant, and all tests were 2-tailed. Multivariable logistic regression analysis was performed to assess the impact of hospital cirrhotic experience on readmission, with adjustment for potential confounders including age, race, gender, homelessness, insurance status, hospital size, hospital characteristics, comorbidity score, disposition, and complications as well as etiologies of cirrhosis. Statistical analyses were performed using SAS ® 9.4 (Cary, NC) and RStudio ® (Boston, MA).
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Results
There were a total of 170,784 eligible hospitalizations, representing 69,612 patients with cirrhosis at 405 hospitals, ranging from 1 to 1687 patients with cirrhosis seen (Fig. 1) . The top 10% of hospitals by cirrhosis volume, serving a median of 747 patients with cirrhosis per hospital (interquartile range [IQR] 450) over the 3-year study period, included 41 hospitals and a total of 24,062 patients. The bottom 90% of hospitals, serving a median of 152.5 patients with cirrhosis per hospital (IQR 243.5), included 364 hospitals and a total of 45,550 patients. 52.7% of the readmissions were to the same hospital as the index hospitalization. The median number of hospital admissions per patient within the study period was 2 (IQR 2). The emergency department was the most frequent source of first admissions (79.4%), followed by home and other (16.5%), and hospital transfer (2.5%); separately, for subsequent admissions, the emergency department was the most frequent source (77.0%), with home and other being less (13.3%), and hospital transfer being relatively more frequent (7.5%) (Supplementary Table 1 ).
There was similar mean age, gender, and race between lower-volume (90%) and higher-volume (10%) hospitals (Table 1 ). Compared to patients at higher-volume hospitals, a larger proportion of patients at lower-volume hospitals had Medicare (42.6 vs. 36.0%) and a smaller proportion had Medicaid (20.4 vs. 25.6%).
Between the two groups, patients from lower-volume hospitals demonstrated a slightly lower level of severity of patient comorbidities as calculated by the Quan-Charlson-Deyo score (average 6.54 vs. 6.68). Patients with HCC were less likely to be admitted to a lower-volume hospital (3.8 vs. 8.7%). Among etiologies of cirrhosis, there was slightly greater burden of alcoholic liver disease (53.1 vs. 47.4%) but lower burden of hepatitis C (34.8 vs. 41.5%) for lower-volume hospitals. Regarding disposition, patients from higher-volume hospitals had a lower proportion of patients discharged to home (66.9 vs. 74.3%) but higher proportion of discharge to other facilities, including skilled nursing facility and intermediate care facilities. The length of stay was not significantly different between lower-volume and higher-volume hospitals (6.10 vs. 6.56 days). The 30-day readmission rate for lower-volume hospitals was 19.1, and 18.2% for higher-volume hospitals.
In the first initial multivariable logistic regression model that includes included hospital cirrhosis patient volume without other hospital characteristics, admission to a hospital with lower cirrhosis patient volume was modestly associated with readmission within 30 days (odds ratio [OR] 1.05, 95% confidence interval [CI] 1.01-1.10) after adjusting for sociodemographics, QCD score, and complications related to cirrhosis (Supplementary Table 2 ). However, in our main multivariate logistic regression model that included additional hospital characteristics derived by linking data from the American Hospital Association survey database, we found that cirrhosis patient volume was no longer an independent risk factor for readmission (OR 0.97, 95% CI 0.92-1.01), while liver transplant center status predicted protection against readmission within 30 days (OR 0.87, 95% CI 0.80-0.94) ( Table 2) .
Notably, Asian or Pacific Islanders (OR 1.19, 95% CI 1.09-1.29) and Native Americans (OR 1.12, 95% CI 1.06-1.18) were more likely to be readmitted compared to whites ( Table 2 ). As expected, increasing Quan-Charlson-Deyo comorbidity score was also a predictor (OR 1.01, 95% 1.00-1.02) of readmission, as were alcoholic liver disease, hepatitis B, and hepatitis C. Patients with both hepatitis B and C did not experience an increase in odds of readmission. Fatty liver disease decreased the odds of readmission (OR 0.79, 95% CI 0.67-0.93). Primary sclerosing cholangitis did not demonstrate an increase in readmissions.
Among cirrhotic complications ( In addition, urban hospitals increased odds of readmission (OR 1.22, 95% CI 1.06-1.40) relative to rural hospitals (Table 2 ). Academic hospitals also experienced an increased odds of readmission (OR 1.14, 95% CI 1.01-1.28). In terms of disposition, relative to discharging home, discharge to short-term hospital (OR 6.57, 95% CI 6.01-7.18) or other facility (such as skilled nursing, intermediate care) [OR 2.05, 95% CI 1.94-2.17], against medical advice (OR 1.72, 95% CI 1.53-1.94), increased odds of readmission, whereas discharge to home health care did not increase the odds of readmission (OR 1.05, 95% CI 0.98-1.13). Hospital bed size had a VIF of 2.38-5.61 concerning for multicollinearity, and as such was excluded from the final regression model.
Discussion
In summary, we leveraged the HCUP California State Inpatient Database to define readmission rates across California between 2009 and 2011 for patients with cirrhosis and identify risk factors for 30-day readmissions in this large, diverse cohort [5] . We have demonstrated that admission to a lower-volume hospital was not a risk factor for readmission with 30 days. Instead, sociodemographic factors and clinical complexity were instead stronger predictors of readmission. While hospital volume as a proxy for cirrhosis experience did not prove to be a statistically significant risk factor for readmission, liver transplant center status significantly decreased odds of readmission (0.87, 95% CI 0.80-0.94). Liver transplant centers comprised 13 hospitals out of 405 hospitals (3.2%), with median hospital volume of 1062 (IQR 1246) patients. One possibility to explain the discrepancy is that being a liver transplant center may provide a degree of experience managing patients with cirrhosis that cannot be provided simply by volume alone. The 30-day readmission rate was 18.8% for our study population. Prior estimates of 30-day readmission rates in patients with cirrhosis have ranged from 13 to 37% [2, 18, 19] . This wide range may be due to regional differences or the fact that some of the studies were limited to a few academic centers. In our cohort, Native Americans were more likely to experience a readmission within 30 days compared to Caucasians (OR 1.12, 95% CI 1.06-1.18), and with longer duration of admission. This is consistent with reports from the Centers for Disease Control and Prevention (CDC), in which liver disease is the fifth leading cause of mortality for Native Americans, compared to sixth for Hispanics, and outside the top 10 causes for Asian or Pacific Islanders, Caucasians, and African Americans [20] . Native Americans comprise 0.5% of the population in California and yet accounted for 15.8% of the admissions in our study [21] .
This study has several limitations. Claims data are subject to error and selection bias. However, since the claims data also are the vehicle by which hospitals are reimbursed, there is particular motivation for diagnoses to be accurately reflected. The database also lacks laboratory results and other clinical information, but this to some measure is compensated for by the Quan modification of the Charlson-Deyo score, a research tool that serves as a reliable surrogate for comorbidities. While Model for End-Stage Liver Disease (MELD) score is not available through this dataset to account for the severity of liver disease, we have accounted for complications of cirrhosis using ICD-9 codes. Additionally, HCUP California does not provide more detail beyond discharge home, short-term hospital transfer, other facility transfers including skilled nursing and intermediate care facility, and home health care. The California dataset does not provide data to account for patients that were discharged to home hospice and death after discharge, which is a competing risk of readmission. However, the home health care cohort, which encompassed home hospice, accounted for only 10.2% of patients and was not statistically significant SD Standard deviation a Home: this HCUP-created category is formally routine disposition, which includes disposition to home or to court/law enforcement (OR 1.05, 95% CI 0.98-1.13). Finally, primary biliary cirrhosis was not included in the analysis as the only available code for this diagnosis (571.6) was not specific enough; however, the impact was likely limited given the relatively small numbers of patients for the available code (n = 1335).
The findings of this study may serve as a barometer for hospitals as they innovate strategies to keep patients with cirrhosis healthy and out of hospitals, improving quality, and driving down cost of care. Many factors relevant to readmission were not modifiable, but identification of specific actionable risk factors may help hospitals target resources appropriately. We found that hospital cirrhosis patient volume was not a risk factor for readmission in California. We instead found that medically complicated patients with cirrhosis at hospitals that were not liver transplant centers were at increased risk of readmission and may benefit from additional support or even transfer to a transplant center to prevent readmission. 
